Published by Josh White on 27th August 2024
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that its lead candidate, bexmarilimab, has been granted fast track designation by the US Food and Drug Administration (FDA), for the treatment of relapsed or refractory myelodysplastic syndrome (r/r MDS) in combination with azacitidine.